Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(4):321-328
Aminoglycosides is one of the main antimicrobial drug classes and continue to play a role in the treatment of several infections, although their relatively high rate of specific adverse reactions. Tobramycin is a typical antibiotic of this class which has a good safety profile and higher (than other aminoglycosides) activity against Pseudomonas aeruginosa (an important pathogen of severe nosocomial infections). The latter characteristic and the development of antimicrobial resistance in Pseudomonas determine the area of tobramycin use in current clinical practice. This review presents pharmacokinetics and pharmacodynamics of tobramycin as well as the results of well-designed clinical trials demonstrating its efficacy in combination with other antimicrobial agents in the treatment of life-threatening infections caused by Pseudomonas. Inhalational use of tobramycin as a potential therapy for patients with cystic fibrosis is not considered in the article.